EUCTR2009-010640-34-IT进行中（未招募）不适用
INDUCTION OF DONOR-SPECIFIC TOLERANCE IN PATIENTS WITH LIVER TRANSPLANTATION WITH RECIPIENT PRE-TREATMENT WITH THYMOGLOBULINE AND MINIMAL POST-TRANSPLANT IMMUNOSUPPRESSION. - ND
AZIENDA OSPEDALIERA POLICLINICO DI MODENA0 个研究点开始时间: 2009年5月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with first liver transplant procedure, even split or living-related, of age > 18 years, giving informed consent to inclusion in the study protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)Re-transplantation with any indication 2)HIV+ patients, or with tumours different from HCC 3)Recipients of multiorgan procedures 4)Patients with severe lymphopenia (< 1000 WBC/ul) or thrombocitopenia (< 50000 PLT/ul) pre-transplantation 5)Female patients in fertile age during pregnancy or breast-feeding
研究者
相似试验
进行中（未招募）
1 期
Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell InfusionRenal FailureNCT00498160Talaris Therapeutics Inc.38
已完成
1 期
Induction of Donor Specific Tolerance in Recipients of Cardiac Allografts by Donor Stem Cell InfusionHeart TransplantationNCT00497757Suzanne T. Ildstad62
No Longer Available
不适用
Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)Renal FailureNCT02051673Talaris Therapeutics Inc.
进行中（未招募）
不适用
Pilot study on tolerability of specific immunotherapywith injective allergoid adsorbed on calcium phosphate in patients with respiratory allergy to house dust mite. - NDallergic rhinoconjunctivitis with or without asthmaMedDRA version: 9.1Level: LLTClassification code 10039085Term: Rhinitis allergicEUCTR2007-003058-26-ITOFARMA
进行中（未招募）
不适用
Induction of Tolerance with Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Severe Systemic Lupus Erythematosus (SLE) Refractory to Standard Immunosuppressive Therapy AN OPEN-LABEL, CONTROLLED, PHASE II MULTICENTER TRIAL OF IMMUNOABLATIVE CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE AND ANTI-THYMOCYTE GLOBULIN AND TRANSPLANTATION OF PURIFIED CD34+ AUTOLOGOUS HEMAPOIETIC STEM CELLS VERSUS CURRENTLY AVAILABLE IMMUNOSUPPRESSIVE THERAPY FOR THE TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS. - ASSISTPatients with systemic lupus erythematosus (SLE) will be under investigation who show high disease activity despite treatment with standard immunosuppressive therapies: high-dose corticosteroids and pulse intravenous CYC at doses of 500-1000mg/m2 for at least 6 months or mycophenolate mofetil (MMF) at doses of at least 2g/d for at least 6 months. Active disease is defined according to BILAG-scoring level A.EUCTR2006-001269-40-DECharité University Medicine30